FDA nod for Novartis sets up cholesterol drug showdown with Amgen, Regeneron


Novartis drug Leqvio now has the FDA’s green light, making it the first RNA interference medicine approved for lowering cholesterol. The regulatory decision sets the stage for competition against cholesterol medicines from Amgen and Regeneron that also address liver protein PCSK9.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.